Literature DB >> 29631432

Early warning biomarkers in major depressive disorder: a strategic approach to a testing question.

R Pratt1, N J C Stapelberg2.   

Abstract

PURPOSE: Identification of biomarkers in major depressive disorder (MDD) has proceeded in an extemporised manner. No single biomarker has been identified with utility in screening, diagnosis, prognosis, or monitoring, and screening tests have different characteristics than the other functions. Using chaos, bifurcation, and perturbation (CBP) theories, the aim is to identify biomarkers to aid clinicians in screening for MDD.
MATERIALS AND METHODS: MDD is a complex disorder; consequently, a reductionist approach to characterize the complex system changes found in MDD will be inchoate and unreliable. A holistic approach is used to identify biomarkers reflecting the tipping points seen before the catastrophic bifurcation that results in MDD.
RESULTS: Applying CBP theories revealed skew, resistance to change, flickering, increased variance and autocorrelation as patterns of biomarkers. Integrals and differentials of extracellular and intracellular biomarkers were identified, specifically focussed on hypothalamo-pituitary axis (HPA) dysfunction, metabolic dysfunction, inflammation and mitochondrial oxidative stress, and tryptophan metabolism.
CONCLUSIONS: Applying CBP theories to the dysfunctional complex biological systems in MDD led to development of integrals and differentials of biomarkers that can be used in screening for MDD and planning future biomarker research, targeting intracellular and extracellular inflammation, HPA axis dysfunction, and tryptophan metabolism.

Entities:  

Keywords:  Bifurcation theory; biomarkers; chaos theory; depression; depression screening; major depressive disorder; perturbation theory

Mesh:

Substances:

Year:  2018        PMID: 29631432     DOI: 10.1080/1354750X.2018.1463563

Source DB:  PubMed          Journal:  Biomarkers        ISSN: 1354-750X            Impact factor:   2.658


  3 in total

1.  A Load to Find Clinically Useful Biomarkers for Depression.

Authors:  Matea Nikolac Perkovic; Marina Sagud; Lucija Tudor; Marcela Konjevod; Dubravka Svob Strac; Nela Pivac
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  Definition and Identification of Patients with Treatment-Resistant Depression in Real-World Clinical Practice Settings Across Asia.

Authors:  Changsu Han; Gang Wang; Sandra Chan; Tadafumi Kato; Chee H Ng; Wilson Tan; Lili Zhang; Yu Feng; Chia-Yih Liu
Journal:  Neuropsychiatr Dis Treat       Date:  2020-12-03       Impact factor: 2.570

3.  Combined serum IL-6, C-reactive protein, and cortisol may distinguish patients with anhedonia in major depressive disorder.

Authors:  Yinghui Li; Yingying Yue; Suzhen Chen; Wenhao Jiang; Zhi Xu; Gang Chen; Zixin Zhu; Liangliang Tan; Yonggui Yuan
Journal:  Front Mol Neurosci       Date:  2022-08-24       Impact factor: 6.261

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.